Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024
‘Investors and entrepreneurs also are wrestling with questions such as the impact of the 2022 Inflation Reduction Act, which enabled Medicare to negotiate prices of certain medications, said David Bearss, chief executive of biotech startup Halia Therapeutics.
“One of the things that is still a driver of the pullback of investment in biotech is uncertainty,” Bearss added.’
Read the full article here (paywall):